The global mRNA therapeutics market size was valued at USD 12.19 billion in 2023 and is projected to surpass around USD 58.90 billion by 2033, registering a CAGR of 17.06% over the forecast period of 2024 to 2033.
mRNA-based therapeutics have generated significant attention in recent years owing to their strong potential in treating chronic diseases. mRNA vaccines provide several benefits over DNA vaccines in terms of production, distribution, and safety. They have shown promise in human clinical studies, increasing the demand for messenger ribonucleic acid-based vaccines and therapeutics. A rise in the number of clinical trials and growing use of stem cell therapies worldwide are driving the market’s expansion.
Government agencies from several nations, research institutions, and numerous biotech & pharmaceutical companies are focusing on efficient & quick methods for detecting COVID-19. In addition, mRNA vaccines are a safe and efficient method for preventing COVID-19. The advantages associated with the COVID-19 messenger RNA vaccines have sparked the attention of pharmaceutical businesses in delivering RNA vaccines swiftly across the globe. As a result, the usage of RNA vaccines is projected to increase during the pandemic. In addition, the mRNA-1273 and BNT162b2 began phase III clinical studies in late July 2020 after positive results in phase I & phase II clinical trials.
It also shows around 94.1% efficacy in symptomatic prevention from COVID-19 and received urgent authorization from the U.S. FDA for widespread immunization of people. Biopharmaceuticals, such as monoclonal antibodies, peptides, and nucleic acids, have attracted significant attention as ground-breaking therapeutic approaches aim to meet the high expectations of treating significant medical illnesses. Moreover, messenger RNA-based technologies have proven to be incredibly promising in treating and preventing several diseases. In addition, technological advancements and scientific study over the past 10 years have made messenger RNA a feasible therapeutic option, eliminating some of the problems with its use, such as its brief half-life and innate immunogenicity.
Hence, the adoption of mRNA therapeutic medicines is expected to increase. Moreover, due to the temporary nature of messenger RNA translation and lack of integration of the foreign material into the cell’s genome, the resulting cellular therapeutic product has numerous benefits over the one obtained by a more conventional approach: easier production under acceptable manufacturing procedures, reduced cytotoxicity from on-target off-tumor effects, and better clinical validation & regulatory treatment. Hence, it is expected to increase the demand for mRNA therapeutics, boosting the market growth.
| Report Attribute | Details |
| Market Size in 2024 | USD 14.27 Billion |
| Market Size by 2033 | USD 58.90 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 17.06% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Application, type, end-use, region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Moderna Inc.; BioNTech SE; CureVac N.V.; Arcturus Therapeutics; Sanofi; GSK Plc.; Argos Therapeutics Inc.; Ethris; Pfizer Inc.; AstraZeneca |
Based on applications, the market is further segmented into rare genetic diseases, oncology, respiratory diseases, infectious diseases, and others. The infectious disease segment held the largest market share of 100% in 2023, primarily owing to the demand for COVID-19 therapeutics. In addition, the increasing adoption of messenger RNA-based vaccines and a growing number of candidates entering clinical trials for various infectious diseases are anticipated to drive the market growth over the forecast period. For instance, in August 2021, Pfizer-BioNTech COVID-19 mRNA vaccine received EUA for prevention of COVID-19 disease in individuals aged 16 years and older.
In addition, in September 2023, BioNTech and Pfizer received the U.S. FDA approval for mRNA-based COVID-19 vaccine COMIRNATY 2023-2024 formulation for individuals aged 12 years and older. Thus, increasing FDA approval of novel mRNA therapeutics is expected to drive the segment. The oncology segment is expected to register the highest CAGR over the forecast period. mRNA technology has shown promising results in cancer research, and there have been ongoing clinical trials exploring the use of RNA vaccines and therapies for various types of cancer. For instance, personalized mRNA cancer vaccines can help stimulate the immune system to target and attack cancer cells.
Based on end-uses, the market is further segmented into hospitals & clinics, research organizations, and others. The hospitals & clinics segment dominated the market with a share of 45.85% in 2023 and is expected to register the fastest growth rate from 2024 to 2033. The widespread use of messenger RNA-based vaccines and therapeutics to treat chronic diseases is expected to boost the market for personalized pharmaceuticals. The segment growth is also likely to be driven by the increasing number of patients visiting hospitals and clinics.
The other segment is expected to register a significant CAGR from 2024 to 2033. The other segment includes specialty pharmacies, which play a vital role in distributing and administering messenger RNA vaccines, primarily due to the unique storage requirements associated with these vaccines. For instance, the Pfizer-BioNTech mRNA COVID-19 vaccine, which initially required ultra-low-temperature storage, benefits significantly from the expertise of specialty pharmacies in handling temperature-sensitive medications.
Based on types, the market is further categorized into prophylactic and therapeutic. The prophylactic segment completely dominated the market with a share of 100% in 2023. COVID-19 products currently account for most prophylactic vaccine revenues. Vaccines for other illnesses, including influenza and respiratory syncytial virus, are expected to contribute to segment growth over the coming years. The clinical trials and development of RNA vaccines for COVID-19, influenza, HIV, and other viral infections are now being undertaken by several key players to strengthen their market positions as well as generate lucrative revenue.
For instance, in February 2023, RVAC Medicines began the phase IB clinical trial for three COVID-19 mRNA vaccine candidates in Singapore after receiving approval from the Health Sciences Authority (HSA). The therapeutics segment is expected to register the highest CAGR from 2024 to 2033. Growing expenditure by key market players to produce novel and effective RNA therapeutics is expected to boost market growth over the forecast years. For instance, in July 2022, Axcelead, Inc.’s subsidiary companies Axcelead Drug Discovery Partners, Inc. and ARCALIS, Inc. came together to offer comprehensive drug discovery support services for messenger RNA-based vaccines and therapeutics.
The North America mRNA therapeutics market accounted for the largest revenue share of 40.75% share in 2023. The availability of significant research funding, the rise in federal programs adopting RNA-based medicines, and increasing number of clinical trials are expected to drive the region’s growth. For instance, in November 2020, The National Institutes of Health (NIH), the Defense Department, and federally funded academic laboratories supported Graham and others’ basic research, which has been a crucial component in the rapid development of vaccinations against COVID-19.
U.S. mRNA Therapeutics Market Trends
The mRNA therapeutics market in the U.S. is expected to grow over the forecast period due to the presence of key market players in the U.S. that are undergoing various strategic initiatives, such as collaborations and partnerships.
Europe mRNA Therapeutics Market Trends
The Europe mRNA therapeutics market is identified as a lucrative region in this industry. This is attributed to strong government support, advancements in research infrastructure, and the success of COVID-19 vaccines based on messenger RNA.
The mRNA therapeutics market in the UK is expected to grow over the forecast period due to growing government deals with companies signed within the country to manage the pandemic, such as COVID-19.
The France mRNA therapeutics market is expected to grow over the forecast period owing to increasing investments by major players in the development of messenger RNA-based vaccines.
The mRNA therapeutics market in Germany is expected to grow over the forecast period due to the presence of a substantial number of providers offering messenger RNA therapeutics and initiatives undertaken to expand the scope of these tools.
Asia Pacific mRNA Therapeutics Market Trends
The Asia Pacific mRNA therapeutics market is anticipated to witness the fastest growth from 2024 to 2033. This growth is attributed to increasing investment in biotechnology, advancements in healthcare infrastructure, and a growing focus on precision medicine. Future trends involve increasing applications beyond infectious diseases to oncology and genetic disorders, with notable examples being China’s investment in messenger RNA research and Japan’s efforts in personalized medicine.
The mRNA therapeutics market in China is expected to grow over the forecast period due to several initiatives undertaken by local companies to advance the messenger ribonucleic acid synthesis landscape.
The Japan mRNA therapeutics market is expected to grow over the forecast period. Major players in the market are adopting several strategies, including mergers & acquisitions, partnerships & collaborations, to stay competitive in the region.
Middle East and Africa mRNA Therapeutics Market Trends
The mRNA therapeutics market in Middle East & Africa (MEA) is witnessing growth propelled by increasing healthcare investments and a rising focus on advanced medical solutions. Drivers include government initiatives, such as the UAE’s commitment to advancing biotechnology and fostering collaborations with mRNA technology developers.
The Saudi Arabia mRNA therapeutics market is expected to grow over the forecast period. Due to the rapidly expanding biologics industry, many globally established players are entering the market and partnering with local players in this country.
The mRNA therapeutics market in Kuwait is expected to grow over the forecast period due to the presence of several multinational and regional pharmaceutical companies in the country.
The market players operating in the mRNA therapeutics market are adopting product approval strategies to increase the reach of their products and improve their availability in diverse geographical areas, along with expansion as a strategy to enhance production/research activities. In addition, several market players are acquiring smaller players to strengthen their market position. This strategy enables companies to increase their capabilities, expand their product portfolios, and improve their competencies.
mRNA Therapeutics Market Top Key Companies:
The following are the leading companies in the mRNA therapeutics market. These companies collectively hold the largest market share and dictate industry trends.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the mRNA Therapeutics market.
By Application
By Type
By End-use
By Region
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Application Segment
1.1.2. Type Segment
1.1.3. End-use Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Nova one advisor Internal Database
1.5.3. Primary Research
1.6. Information or Data Analysis:
1.6.1. Data Analysis Models
1.7. Market Formulation & Validation
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. List of Abbreviations
1.11. Objective
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising prevalence of cancer
3.2.1.2. Academic and industrial interest in mRNA
3.2.1.3. Advantages of mRNA vaccines
3.2.1.4. Growing demand for therapeutic medicines
3.2.2. Market Restraint Analysis
3.2.2.1. Stringent government regulations for mRNA-based product approvals
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Application Business Analysis
4.1. Application Segment Dashboard
4.2. mRNA Therapeutics Market Application Movement Analysis
4.3. mRNA Therapeutics Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
4.4. Rare Genetic Diseases
4.4.1. Rare genetic diseases market estimates and forecasts, 2021 - 2033
4.5. Oncology
4.5.1. Oncology market estimates and forecasts, 2021 - 2033
4.6. Respiratory Diseases
4.6.1. Respiratory diseases market estimates and forecasts, 2021 - 2033
4.7. Infectious Diseases
4.7.1. Infectious diseases market estimates and forecasts, 2021 - 2033
4.8. Others
4.8.1. Others market estimates and forecasts, 2021 - 2033
Chapter 5. Type Business Analysis
5.1. Type Segment Dashboard
5.2. mRNA Therapeutics Market Type Movement Analysis
5.3. mRNA Therapeutics Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
5.4. Prophylactic
5.4.1. Prophylactic market estimates and forecasts, 2021 - 2033
5.5. Therapeutic
5.5.1. Therapeutic market estimates and forecasts, 2021 - 2033
Chapter 6. End-use Business Analysis
6.1. End-use Segment Dashboard
6.2. mRNA Therapeutics Market End-use Movement Analysis
6.3. mRNA Therapeutics Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
6.4. Hospitals & Clinics
6.4.1. Hospitals & clinics market estimates and forecasts, 2021 - 2033
6.5. Research Organizations
6.5.1. Research organizations market estimates and forecasts, 2021 - 2033
6.6. Others
6.6.1. Others market estimates and forecasts, 2021 - 2033
Chapter 7. Regional Business Analysis by Application, Type, End-use
7.1. Regional Dashboard
7.2. Market Size & Forecast and Trend Analysis, 2023 & 2030
7.3. North America
7.3.1. North America mRNA Therapeutics Market, 2021 - 2033
7.3.2. U.S.
7.3.2.1. Key Country Dynamics
7.3.2.2. Competitive Scenario
7.3.2.3. Market Scenario
7.3.2.4. Regulatory Framework
7.3.2.5. Disease Prevalence
7.3.2.6. Reimbursement Scenario
7.3.2.7. U.S. mRNA Therapeutics Market, 2021 - 2033
7.3.3. Canada
7.3.3.1. Key Country Dynamics
7.3.3.2. Competitive Scenario
7.3.3.3. Market Scenario
7.3.3.4. Regulatory Framework
7.3.3.5. Disease Prevalence
7.3.3.6. Reimbursement Scenario
7.3.3.7. Canada mRNA Therapeutics Market, 2021 - 2033
7.4. Europe
7.4.1. Europe mRNA Therapeutics Market, 2021 - 2033
7.4.2. UK
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Market Scenario
7.4.2.4. Regulatory Framework
7.4.2.5. Disease Prevalence
7.4.2.6. Reimbursement Scenario
7.4.2.7. UK mRNA Therapeutics Market, 2021 - 2033
7.4.3. Germany
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Market Scenario
7.4.3.4. Regulatory Framework
7.4.3.5. Disease Prevalence
7.4.3.6. Reimbursement Scenario
7.4.3.7. Germany mRNA Therapeutics Market, 2021 - 2033
7.4.4. France
7.4.4.1. Key Country Dynamics
7.4.4.2. Competitive Scenario
7.4.4.3. Market Scenario
7.4.4.4. Regulatory Framework
7.4.4.5. Disease Prevalence
7.4.4.6. Reimbursement Scenario
7.4.4.7. France mRNA Therapeutics Market, 2021 - 2033
7.4.5. Italy
7.4.5.1. Key Country Dynamics
7.4.5.2. Competitive Scenario
7.4.5.3. Market Scenario
7.4.5.4. Regulatory Framework
7.4.5.5. Disease Prevalence
7.4.5.6. Reimbursement Scenario
7.4.5.7. Italy mRNA Therapeutics Market, 2021 - 2033
7.4.6. Spain
7.4.6.1. Key Country Dynamics
7.4.6.2. Competitive Scenario
7.4.6.3. Market Scenario
7.4.6.4. Regulatory Framework
7.4.6.5. Disease Prevalence
7.4.6.6. Reimbursement Scenario
7.4.6.7. Spain mRNA Therapeutics Market, 2021 - 2033
7.4.7. Denmark
7.4.7.1. Key Country Dynamics
7.4.7.2. Competitive Scenario
7.4.7.3. Regulatory Framework
7.4.7.4. Disease Prevalence
7.4.7.5. Reimbursement Scenario
7.4.7.6. Denmark mRNA Therapeutics Market, 2021 - 2033
7.4.8. Sweden
7.4.8.1. Key Country Dynamics
7.4.8.2. Market Scenario
7.4.8.3. Regulatory Framework
7.4.8.4. Disease Prevalence
7.4.8.5. Reimbursement Scenario
7.4.8.6. Sweden mRNA Therapeutics Market, 2021 - 2033
7.4.9. Norway
7.4.9.1. Key Country Dynamics
7.4.9.2. Competitive Scenario
7.4.9.3. Regulatory Framework
7.4.9.4. Disease Prevalence
7.4.9.5. Reimbursement Scenario
7.4.9.6. Norway mRNA Therapeutics Market, 2021 - 2033
7.5. Asia Pacific
7.5.1. Asia Pacific mRNA Therapeutics Market, 2021 - 2033
7.5.2. Japan
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Framework
7.5.2.4. Reimbursement Scenario
7.5.2.5. Japan mRNA Therapeutics Market, 2021 - 2033
7.5.3. China
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Framework
7.5.3.4. Reimbursement Scenario
7.5.3.5. China mRNA Therapeutics Market, 2021 - 2033
7.5.4. India
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Framework
7.5.4.4. Reimbursement Scenario
7.5.4.5. India mRNA Therapeutics Market, 2021 - 2033
7.5.5. Australia
7.5.5.1. Key Country Dynamics
7.5.5.2. Competitive Scenario
7.5.5.3. Regulatory Framework
7.5.5.4. Reimbursement Scenario
7.5.5.5. Australia mRNA Therapeutics Market, 2021 - 2033
7.5.6. Thailand
7.5.6.1. Key Country Dynamics
7.5.6.2. Competitive Scenario
7.5.6.3. Regulatory Framework
7.5.6.4. Reimbursement Scenario
7.5.6.5. Thailand mRNA Therapeutics Market, 2021 - 2033
7.5.7. South Korea
7.5.7.1. Key Country Dynamics
7.5.7.2. Competitive Scenario
7.5.7.3. Regulatory Framework
7.5.7.4. Reimbursement Scenario
7.5.7.5. South Korea mRNA Therapeutics Market, 2021 - 2033
7.6. Latin America
7.6.1. Latin America mRNA Therapeutics Market, 2021 - 2033
7.6.2. Brazil
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Framework
7.6.2.4. Reimbursement Scenario
7.6.2.5. Brazil mRNA Therapeutics Market, 2021 - 2033
7.6.3. Mexico
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Framework
7.6.3.4. Reimbursement Scenario
7.6.3.5. Mexico mRNA Therapeutics Market, 2021 - 2033
7.6.4. Argentina
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Framework
7.6.4.4. Reimbursement Scenario
7.6.4.5. Argentina mRNA Therapeutics Market, 2021 - 2033
7.7. MEA
7.7.1. MEA mRNA Therapeutics Market, 2021 - 2033
7.7.2. South Africa
7.7.2.1. Key Country Dynamics
7.7.2.2. Competitive Scenario
7.7.2.3. Market Scenario
7.7.2.4. Regulatory Framework
7.7.2.5. Disease Prevalence
7.7.2.6. Reimbursement Scenario
7.7.2.7. South Africa mRNA Therapeutics Market, 2021 - 2033
7.7.3. Saudi Arabia
7.7.3.1. Key Country Dynamics
7.7.3.2. Competitive Scenario
7.7.3.3. Regulatory Framework
7.7.3.4. Reimbursement Scenario
7.7.3.5. Saudi Arabia mRNA Therapeutics Market, 2021 - 2033
7.7.4. UAE
7.7.4.1. Key Country Dynamics
7.7.4.2. Competitive Scenario
7.7.4.3. Regulatory Framework
7.7.4.4. Reimbursement Scenario
7.7.4.5. UAE mRNA Therapeutics Market, 2021 - 2033
7.7.5. Kuwait
7.7.5.1. Key Country Dynamics
7.7.5.2. Competitive Scenario
7.7.5.3. Regulatory Framework
7.7.5.4. Reimbursement Scenario
7.7.5.5. Kuwait mRNA Therapeutics Market, 2021 - 2033
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Market Position Analysis, 2023
8.4. Company Profiles/Listing
8.4.1. Moderna Inc.
8.4.1.1. Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. BioNTech SE
8.4.2.1. Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. CureVac N.V.
8.4.3.1. Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Arcturus Therapeutics
8.4.4.1. Overview
8.4.4.2. Product Benchmarking
8.4.4.3. Strategic Initiatives
8.4.5. Sanofi
8.4.5.1. Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. GSK plc.
8.4.6.1. Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. Argos Therapeutics Inc.
8.4.7.1. Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. Ethris
8.4.8.1. Overview
8.4.8.2. Product Benchmarking
8.4.8.3. Strategic Initiatives
8.4.9. Pfizer Inc.
8.4.9.1. Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. AstraZeneca
8.4.10.1. Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers